BioCentury
ARTICLE | Company News

Acumen, Merck Alzheimer's deal

January 13, 2004 8:00 AM UTC

Acumen Pharmaceuticals (San Francisco, Calif.) granted MRK exclusive worldwide rights to its amyloid-derived diffusible ligand (ADDL) target for use in developing monoclonal antibodies and vaccines to...